Tags : Men

Myovant Sciences Reports Results of Relugolix in P-III HERO Study

Shots: The P-III HERO study involves assessing of Relugolix (360mg loading dose followed by 120mg, qd) vs leuprolide acetate (3mos. depot injection) in men in ratio 2:1 with androgen-sensitive advanced prostate cancer requiring at least 1yr. of continuous androgen deprivation therapy The P-III HERO study resulted in meeting its 1EPs & all six key 2EPs […]Read More

Myriad to File sPMA to the US FDA of BRACAnalysis

Shots: Myriad to seek approval based on the P-III PROfound results assessing Lynparza vs enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have failed prior treatment with the hormonal agent with homologous recombination repair gene mutations In 2007, Myriad & AstraZeneca entered into collaboration on Lynparza and has resulted in multiple […]Read More

Astellas Reports Results of Mirabegron in P-IV PLUS Study to

Shots: The P-IV PLUS study involves assessing of Mirabegron(25mg,50mg) vs PBO in 715 men patients with overactive bladder (OAB) symptoms receiving tamsulosin for lower urinary tract symptoms (LUTS) due to underlying benign prostatic hyperplasia (BPH) aged ≥40 yrs. The P-IV PLUS study results: @12wks. reduction in no. of micturition/day, increment in mean volume voided (MVV)/micturition, […]Read More